Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice

International Journal of Cancer

Volumn 73, Issue 3, 1997, Pages 371-380

  Lala, P K ^a,b   Al Mutter, N ^a   Orucevic, A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Faculty of Medicine   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRINKING WATER; INDOMETACIN; PROSTAGLANDIN E;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOARCHITECTURE; DRUG EFFECT; MALIGNANT TRANSFORMATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION;

AGE OF ONSET; ANIMALS; ANTICARCINOGENIC AGENTS; FEMALE; INDOMETHACIN; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C3H; NEOPLASM PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS E; TIME FACTORS;

EID: 0030663230     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971104)73:3<371::AID-IJC12>3.0.CO;2-G     Document Type: Article

References (41)

1. ALLISON, A.C. and KOWALSKI, W.J., Prostaglandins as transducers of proliferation signals in microvascular endothelial cells and the pharmacological control of angiogenesis. In: J.D. Catravas, C.N. Gillis and U.S. Ryan (eds.), Vascular endothelium: receptors and transduction mechanisms, pp. 99-110, Plenum, New York (1984).
2. ALTMANN, G.G., and LALA, P.K., Hyperplasia of mouse duodenal crypts and its control by NK cells during the initial phase of DMH carcinogenesis. Int. J. Cancer, 46, 695-702 (1990).
3. ALTMANN, G.G. and LALA, P.K., Initiated stem cells in murine intestinal carcinogenesis: prolonged survival, control by NK cells and progression. Int. J. Cancer, 59, 569-579 (1994).
4. BARNABAS-SOHI, N., SIMHA, M.R., PARIKH, V.A., FEUILHADE, F., KURKURE, A., KOUYOUMDJIAN, J.C., JUSSAWALLA, D.J., DOCTOR, V.M. and THERWATH, A., Breast carcinoma in a high-risk population: structural alterations in neu, int-2 and p53 genes. Breast Dis., 6, 13-26 (1993).
5. BATTISIMI, B., BOTTING, R. and BAKHIE, Y.S., Cox-1 and Cox-2: towards the development of more selective NSAIDS. Drug News Perspect., 7, 501-512 (1994).
6. 2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer, 72, 491-501 (1993).
7. BENNET, A., CHARLIER, E.M., MCDONALD, A.M., SIMPSON, J.S., STAMFORD, I.F. and ZEBRO, T., Prostaglandins and breast cancer. Lancet, 2(8039), 624-626 (1977).
8. BRUNDA, M.J., HERBERMAN, R.B. and HOLDEN, H.T., Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol., 124, 2682-2687 (1980).
9. CAMERON, D.J. and O'BRIEN, P., Relationship of the suppression of macrophage mediated tumor cytotoxicity in conjunction with secretion of prostaglandin from the macrophages of breast cancer patients. Int. J. Immunopharmacol., 4, 445-450 (1982).
10. CONNOLLY, J.M. and ROSE, D.P., Effects of fatty acids on invasion through reconstituted basement (Matrigel) by a human breast cancer cell line. Cancer Lett., 137-142 (1993).
11. 2 and angiogenesis. Proc. Soc. exp. Biol. Med., 172, 214-218 (1983).
12. GALLAHAN, D., KOZAK, C. and CALLAHAN, R., A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17, J. Virol., 61, 218-220 (1987).
13. KARGMAN, S.L., O'NEILL, G.P., VICKERS, P.J., EVANS, J.F., MANCINI, J.A. and JOTHY, S., Expression of prostaglandin G/H synthase 1 and 2 protein in human colonic cancer. Cancer Res., 55, 2556-2559 (1995).
14. KHOO, N.K.S., CHAN, F.P.H., SAARLOOS, M.N. and LALA, P.K., Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Clin. exp. Metastasis, 10, 239-252 (1992).
15. KURUMBAIL, R.G., STEVENS, A.M., GIERSE, J.K., MCDONALD, J.J., STEGEMAN, R.A., PAK, J.Y., GILDHAUS, D., MIYASHIRO, J.M., PENNING, T.D., SEIBERT, K., ISAKSON, P.C. and STALLING, W.C., Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature (Lond), 384, 644-648 (1996).
16. LALA, P.K., ELKASHAB, M., KERBEL. R.S. and PARHAR, R.S., Cure of human melanoma lung metastasis in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. Int. Immunol., 2, 1149-1158 (1990a).
17. LALA, P.K. and PARHAR, R.S., Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin-2: characteristics of killer cells generated in situ. Cancer Res., 48, 1072-1079 (1988).
18. LALA, P.K. and PARHAR, R.S., Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int. J. Cancer. 54, 677-684 (1993).
19. LALA, P.K., PARHAR, R.S. and SINGH, P., Indomethacin abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell. Immunol., 99, 108-118 (1986).
20. LALA, P., PARHAR, R.S., SINGH, P. and LALA, P.K., Cure of murine Ehrlich ascites tumors with chronic oral indomethacin therapy combined with intraperitoneal administration of LAK cells and IL-2. Cancer Lett., 51, 27-35 (1990b).
21. LALA, P.K. and SAARLOOS, M.N., Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy. In: J.E. Harris, D.P. Braun and K.M. Anderson (eds.), Prostaglandin inhibitors in tumor immunology and immunotherapy, pp. 187-227. CRC Press, Boca Raton (1994).
22. LALA, P.K., SANTER, V., LIBENSON, H. and PARHAR, R.S., Changes in the host natural killer cell population in mice during tumor development. 1. Kinetics and in vivo significance. Cell. Immunol., 93, 250-264 (1985).
23. LIU, X.H. and ROSE, D.P., Stimulation of type IV collagenase expression by linoleic acid in a metastatic human breast cancer cell line. Cancer Lett., 76, 71-77 (1994).
24. MASFERRER, J.L., ZWEIFEL, B.S., MANNING, P.T., HAUSER, S.D., LEAHY, K.M. SMITH, W.G., ISAKSON, P.C. and SEIBERT, K., Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc. nat. Acad. Sci. (Wash.), 91, 3228-3232 (1994).
25. MERTENS, W.C., BRAMWELL, V.H.C., BANERJEE, D., GWADRY-SRIDHAR, F. and LALA, P.K., Chronic oral indomethacin and ranitidine with intermittent continuous infusion IL-2 in advanced malignant melanoma: a phase 2 study. Clin. Oncol. 5, 97-113 (1993a).
26. MERTENS, W.C., BRAMWELL, V.H.C., BANERJEE, D., GWADRY-SRIDHAR, F., AL-MUTTER, N., PARHAR, R.S. and LALA, P.K., Chronic oral indomethacin and ranitidine with intermittent continuous infusion IL-2 in advanced renal cell carcinoma. Cancer Biother., 8, 229-233 (1993b).
27. MERTENS, W.C., BRAMWELL, V.H.C., GWADRY-SRIDHAR, F., ROMANO, W., BANERJEE, D. and LALA, P.K., Combination of indomethacin and ranitidine in advanced melanoma patients on high dose interleukin-2. Lancet. 340, 397-398 (1992).
28. MIZUKAMI, Y., NONOMURA, A., NOGUCHI, M., TANYA, T., THOMAS, M., NAKAMURA, S. and MIYAZAKI, I., Effects of high and low dietary fat and indomethacin on tumour growth, hormone receptor status and growth factor expression in DMBA-induced rat breast cancer. Int. J. Tissue React., 14, 269-276 (1992).
29. MORRIS, V.L., RAO, T.R., KOZAK, C.A., GRAY, D.A., LEE CHAN, E.C.M., CORNELL, T.J., TAYLOR, C.B., JONES, R.F. and MCGRATH, C.M., Characterization of lnt-5, a locus associated with early events in mammary carcinogenesis. Oncogene Res., 6, 53-63 (1991).
30. NUSSE, R. and VARMUS, H.E., Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 31, 99-109 (1982).
31. PARHAR, R.S., CHAMBERS, A. and LALA, P.K., A comparison of the efficacy of indomethacin. IL-2, IFN-γ or their various combinations in the treatment of experimental murine lung metastasis. Proc. 19th Int. Leukocyte Culture Conference, 80 (Abstract) (1988).
32. PARHAR, R.S. and LALA, P.K., Changes in the host natural killer cell population during tumor development. 2. The mechanism of suppression of NK activity. Cell. Immunol., 93, 265-279 (1985).
33. PARHAR. R.S. and LALA, P.K., Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin-2. J. exp. Med., 165, 14-28 (1987).
34. 2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J. Leukocyte Biol., 44, 474-484 (1988).
35. PETERS, G., BROOKES, S., SMITH, R. and DICKSON, C., Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell. 33, 369-377 (1983).
36. SALMONS, B. and GUNZBURG, W.H., Current perspectives in the biology of the mouse mammary tumor virus. Virus Res., 8, 81-102 (1987).
37. SANTER, V., MASTROMARINO, J.H. and LALA, P.K., Characterization of lymphocyte subsets in spontaneous mouse mammary tumors and host lymphoid organs. Int. J. Cancer, 25, 159-168 (1980).
38. SCHREINEMACHERS, D.M. and EVERSON, R.B., Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology, 5, 138-146 (1994).
39. WANG, Y., HOLLAND, J.F., BLEIWEISS, I.J., MELANA, S., LIU, X., PELISSON, I., CANTARELLA, A., STELLRECT, K., MANI, S. and POGO, B.G.-T., Detection of mammary tumor virus ENV gene-like sequences in human breast cancer. Cancer Res., 55, 5173-5179 (1995).
40. 2-responsive metastatic Lewis lung carcinoma cells. Cancer Res., 47, 3679-3683 (1987).
41. ZAR, J.H., Biostatistical analysis. Prentice Hall, Englewood Cliffs, NJ (1974).